Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) With Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results From the Pyramid Trial (NCT00931918).

× No keyword cloud information.

13 in total

Review 1. Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice.

Authors: Elaine S Jaffe; Paul M Barr; Sonali M Smith
Journal: Am Soc Clin Oncol Educ Book Date: 2017

Review 2. Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.

Authors: Grzegorz S Nowakowski; Kristie A Blum; Brad S Kahl; Jonathan W Friedberg; Lawrence Baizer; Richard F Little; David G Maloney; Laurie H Sehn; Michael E Williams; Wyndham H Wilson; John P Leonard; Sonali M Smith
Journal: J Natl Cancer Inst Date: 2016-12-16 Impact factor: 13.506

Review 3. Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?

Authors: Andrew Davies
Journal: Hematology Am Soc Hematol Educ Program Date: 2017-12-08

4. Prognostic modeling in diffuse large B-cell lymphoma in the era of immunochemotherapy: Where do we go from here?

Authors: Jean L Koff; Christopher R Flowers
Journal: Cancer Date: 2017-05-02 Impact factor: 6.860

5. Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma.

Authors: Qiushi Chen; Ashley D Staton; Turgay Ayer; Daniel A Goldstein; Jean L Koff; Christopher R Flowers
Journal: Leuk Lymphoma Date: 2017-10-25

Review 6. Molecular Subtyping in Diffuse Large B Cell Lymphoma: Closer to an Approach of Precision Therapy.

Authors: Reem Karmali; Leo I Gordon
Journal: Curr Treat Options Oncol Date: 2017-02

7. Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics.

Authors: Yi-An Zhang; Xue Yang; Jiamei Yao; Yuhong Ren; Peng Liu
Journal: Dis Markers Date: 2022-06-21 Impact factor: 3.464

Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) With Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results From the Pyramid Trial (NCT00931918).